Skip to main content

Hemophilia B

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B
NCT02396342 | PHASE 1 | INTERVENTIONAL

This study evaluates how safe gene therapy treatment with AAV5-hFIX is in adult patients with severe or moderately severe hemophilia B and severe bleeding type.

Trial Information
7 Sites
10 Participants
Recruiting
18 Years to 50 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

uniQure Investigative Site
Copenhagen,Denmark
uniQure Investigative Site
Berlin,Germany
uniQure Investigative Site
Frankfurt,Germany
uniQure Investigative Site
Amsterdam,Netherlands
uniQure Investigative Site
Groningen,Netherlands
uniQure Investigative Site
Rotterdam,Netherlands
uniQure Investigative Site
Utrecht,Netherlands

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov